AMGN - Old is Gold = Value Buy!
Robust cash (total cash: $17.6b, Lt. Debt: $20.2b) and attractive valuations along with dividend payout and philosophy to pursue “innovation” in a balanced way should keep shareholders interested in AMGN for long term. PhIII data from study ‘147 published in The Lancet found that XGEVA significantly prolonged bone metastasis-free survival, delayed time to bone metastasis and reduced the risk of symptomatic bone metastases. Based on the data, we are optimistic about its approval in… Restructuring in R&D – reduction in headcount and discontinued two PhII programs – Conatumumab (AMG 655) for various cancers and AMG 827 for Crohn’s disease. Operating margins will improve from… For more detail, please read our report released on 25th November on AMGN titled “AMGN - Old is Gold = Value Buy!”
COMPANIES MENTIONED
AMGEN
AMGEN
More Publications
Outlook 2012 - Mature Biotech - Investing in Growth and Value buys!
US$ 2,000.00
December 2011
46 pages
AMGEN, Outperform, GILEAD, Outperform - Gilead and Amgen - Offer Long Term Value
US$ 140.00
June 2011
10 pages
Analyzing the Major Gold Mines Worldwide
US$ 300.00
March 2012
100 pages
